Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Siemens Nears Start Of Nuclear-Medicine Production In India

This article was originally published in PharmAsia News

Executive Summary

Siemens AG, a Germany-based drug maker, is set to begin producing nuclear medicines in India, with its first plant now set up in Chennai and as many as five others in the works. Part of the process involves getting approval from India's Atomic Energy Regulatory Board, to which Siemens has applied. A Siemens official said multiple plants are involved because of the quick loss of potency of radiopharmaceuticals, so they need to be closer to hospitals in each region. Siemens expects to invest as much as $4 million in each of the facilities and begin manufacturing with the FDG biomarker for diagnosing and treating cancer. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts